May 23, 2022

MindMed Appoints Schond L. Greenway as Chief Financial Officer

Welcome aboard! Your submission has been received and you are now a member of the community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.
Subscribe to Excellence

NEW YORK, May 23, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.

"We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech capital markets, which was a key attribute we sought in identifying a CFO. Schond is joining MindMed at an exciting point in our growth, with numerous near-term milestones ahead across our pipeline. I look forward to working closely with him to advance our mission of becoming a global leader in the development of innovative therapies for brain health disorders."
~ Robert Barrow, Chief Executive Officer and Director of MindMed
"This is an exciting time to be joining the Company as it continues its patient-focused mission of developing innovative new therapies to improve outcomes for individuals with anxiety, addiction and autism. I'm excited to join this dynamic and talented team. I look forward to working with the management team to advance the Company's robust pipeline and contribute to its success."
~ Schond L. Greenway, Chief Financial Officer of MindMed

Mr. Greenway joins MindMed after serving as CFO of Avalo Therapeutics, a precision medicine clinical stage biopharmaceutical company.  He previously served as VP of Investor Relations at Mesoblast, an allogeneic cellular medicines company. He served in a similar role at Halozyme Therapeutics, Inc. and in various roles at investment banking firms Morgan Stanley and Barclays Capital, predominantly focused on healthcare and technology. Mr. Greenway has participated in and advised on numerous transactions during his tenure in investment banking and capital markets. He has assisted in securing significant cumulative growth capital through a variety of equity and debt instruments in the public and private markets, as well as through funding from significant collaboration arrangements with therapeutics companies.

Mr. Greenway received an MBA from the Darden Graduate School of Business – University of Virginia and a BS from Florida A&M University.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media:
For Investors:

View original content to download multimedia:

SOURCE Mind Medicine (MindMed) Inc.

View original content to download multimedia:


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on for important risk disclosures. It’s your money and your responsibility.